XML 77 R65.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Shareholders' Equity - Additional Information (Details) - EUR (€)
 6 Months Ended 12 Months Ended
Apr. 30, 2025
Feb. 02, 2025
Jan. 29, 2025
Apr. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jun. 24, 2024
Jan. 31, 2024
Disclosure of classes of share capital [Line Items]                  
Share capital         € 2,455,512,548        
Number of shares (in shares)         1,227,756,274        
Par value per share (in euros per share)         € 2        
Number of restricted shares vested (in shares)         2,682,051        
Number of restricted shares alloted in regards of capital increase         1,525,846        
Other comprehensive income that will be reclassified to profit or loss, net of tax         € (5,318,000,000) € 1,067,000,000 [1]      
Cancellation of treasury shares         € 3,868,000,000        
Employees share ownership plan                  
Disclosure of classes of share capital [Line Items]                  
Subscription price (in euros per share)     € 72.97           € 72.87
Number of shares subscribed (in shares)         2,260,776     2,124,445  
Number of shares issued immediately for employer's contribution (in shares)         116,794     119,951  
Expense recognized         € 31,000,000 45,000,000      
Share Repurchase 2024 Program                  
Disclosure of classes of share capital [Line Items]                  
Period of share repurchase program 18 months     18 months          
Number of shares repurchased (in shares)         39,344,633        
Amount of shares repurchased         € 3,988,000,000        
Share Repurchase 2025 Program                  
Disclosure of classes of share capital [Line Items]                  
Number of shares repurchased (in shares)         29,556,650        
Amount of shares repurchased   € 3,000,000,000 € 5,000,000,000            
Per Share Value of Shares Repurchased   € 101.50              
Share capital | Sanofi                  
Disclosure of classes of share capital [Line Items]                  
Capital increase by exercise of stock subscription options (in shares)         171,150        
Capital increase by issuance of restricted shares (in shares)         1,156,205        
Other comprehensive income | Items subsequently reclassifiable to profit or loss                  
Disclosure of classes of share capital [Line Items]                  
Other comprehensive income that will be reclassified to profit or loss, net of tax         € (5,017,000,000) € 1,067,000,000      
Other comprehensive income | Foreign Currency Translation | Items subsequently reclassifiable to profit or loss                  
Disclosure of classes of share capital [Line Items]                  
Other comprehensive income that will be reclassified to profit or loss, net of tax         € 459,000,000   € 5,000,000    
[1] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.